So far ROS has been shown to activate MMP‐2, a key protease in cardiovascular diseases. This study tested whether MMP‐2´s effect on vascular dysfunction was mediated by ROS. The cDNA of the catalytic domain of the human MMP‐2 was cloned in fusion with GFP, and the activity of the hMMP‐2cat/GFP was assayed. The rhMMP‐2/GFP protein was catalytically active (both were expressed and purified from E coli). Both proteins were injected into the lumen of New Zealand rabbit aortas, and filled vessels (MMP‐2‐FA) were incubated for 30 min. Concentration used: 1.2 ug/ml or 16 mmol/L, 4 times the level of MMP‐2 found in healthy humans. The exogenous MMP‐2 increase in aortic wall was tracked by direct observation of GFP, immunostaining and gelatinolytic activity. This last parameter doubled in the MMP‐2‐FA, as well as in MMP‐2‐FA+PMSF (a serine‐proteinase inhibitor), but displayed normal values in MMP‐2‐FA+ Doxycycline (an MMP inhibitor). ROS activity was increased by 85% (±4%) in MMP‐2‐FA, while there was only a slight increase in the MMP‐2‐FA co‐infused with the MMP inhibitor Doxycycline (15 ±8%). Apocinin and PEG Catalase decreased the levels of ROS in MMP‐2‐FA to basal levels (P<0.001), while Tiron only reduced ROS levels by 17%(±8%)(p<0.05). This is the first study to show that MMP‐2 at levels described in plasma of patients are sufficient to increase ROS in vessels.Grant Funding Source: FAPESP
Read full abstract